Managing Director
Dr. Thomas J. Fogarty is an internationally recognized cardiovascular surgeon, inventor, entrepreneur, and investor. He has been involved with a wide spectrum of innovations in business and technology, serving as founder/co-founder, and Chairman/board member of over 30 medical device companies, the majority based on devices designed and developed by Fogarty Engineering, Inc. Dr. Fogarty has published approximately 180 scientific articles and textbook chapters in fields of general and cardiovascular surgery, and is the author or co-author of more than 125 patents and patent applications. His patents include the “industry standard” Fogarty balloon embolectomy catheter (now owned by Edwards Lifesciences), and the widely used Aneurx Stent Graft (now owned by Medtronic). Dr. Fogarty is the recipient of countless awards and honors; most significantly, he is the recipient of the Jacobson Innovation Award of the American College of Surgeons, the 2000 Lemelson-MIT prize for Invention and Innovation and was inducted into the Inventors Hall of Fame in December 2001. Dr. Fogarty is currently Clinical Professor of Surgery at Stanford University. Previously, he has held positions as President, Medical Staff at Stanford University Medical Center, and Director, Cardiovascular Surgery at Sequoia Medical Center. Dr. Fogarty was born in Cincinnati, Ohio and received his undergraduate education at Xavier University and his medical degree from the University of Cincinnati. He completed his residency at the University of Oregon. Dr. Fogarty was a founder and general partner of Three Arch Partners, and a general partner in five successive Three Arch venture funds.
Managing Director
Allan has been a founder, board member and/or CEO of a number of early stage companies in medical device and biotechnology including Athenagen (an LSA company), MAST Immunosystems, Intella Interventional Systems, Quanam Medical, ImmuneTech, NuGEN Technologies, AngstroVision, IntegriGen, Imetrx, and Vascular Architects. Previously, Mr. May was Senior Vice President of Diasonics, Inc., a NYSE-listed medical imaging company manufacturing and distributing MRI, ultrasound, fluoroscopic and therapeutic devices, and President and COO of Fortune Systems Corporation, a NASDAQ-traded developer of microprocessor based file servers utilizing the Unix operating system. He also has extensive experience in negotiating and consummating mergers and acquisitions, having been involved in over 100 transactions. He co-founded Life Science Angels (“LSA”) in 2005 and currently serves as its Chairman. LSA is the largest angel organization in the United States comprised solely of life science industry veterans and investing solely in medical device and life science early stage companies.
Managing Director
Bob has a broad range of business development, legal and management experience. With 20 years of counseling life sciences companies from formation to maturity, Bob has a wealth of experience that benefits portfolio companies. Before joining Emergent he was a partner at MedVenture Associates, a medtech venture capital firm. Prior to becoming a venture capitalist, Bob was Vice President and General Counsel of TheraSense, Inc., where he was a key member of the company’s management team. He joined TheraSense while it was still a private company after serving as its outside counsel since its initial incorporation. Bob left TheraSense following its acquisition and integration with Abbott Laboratories. Prior to TheraSense Bob was a corporate and securities partner at Wilson Sonsini Goodrich & Rosati, where he worked for twelve years following law school. His practice focused on the representation of technology companies from their earliest stages with an emphasis on life sciences companies. Bob received his J.D. from UCLA Law School and has a B.A. from the University of California at Berkeley.